Medical News Today -
28 Jan 2014 12:00
Miltenyi Biotec has announced that the U.S. Food and Drug Administration (FDA) has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) in first complete remission undergoing allogeneic stem cell transplantation (SCT) from a matched related donor.
Share this Article